|
1
|
Jiang C, Li X, Zhao H and Liu H: Long
non-coding RNAs: Potential new biomarkers for predicting tumor
invasion and metastasis. Mol Cancer. 15:622016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Long J, Zhang CJ, Zhu N, Du K, Yin YF, Tan
X, Liao DF and Qin L: Lipid metabolism and carcinogenesis, cancer
development. Am J Cancer Res. 8:778–791. 2018.PubMed/NCBI
|
|
3
|
Gómez de Cedrón M and Ramírez de Molina A:
Microtargeting cancer metabolism: Opening new therapeutic windows
based on lipid metabolism. J Lipid Res. 57:193–206. 2016.
View Article : Google Scholar :
|
|
4
|
Huang C and Freter C: Lipid metabolism,
apoptosis and cancer therapy. Int J Mol Sci. 16:924–949. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo X, Cheng C, Tan Z, Li N, Tang M, Yang
L and Cao Y: Emerging roles of lipid metabolism in cancer
metastasis. Mol Cancer. 16:762017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deep G and Schlaepfer IR: Aberrant Lipid
Metabolism Promotes Prostate Cancer: Role in Cell Survival under
Hypoxia and Extracellular Vesicles Biogenesis. Int J Mol Sci.
17:172016. View Article : Google Scholar
|
|
7
|
Duan J, Chen L, Zhou M, Zhang J, Sun L,
Huang N, Bin J, Liao Y and Liao W: MACC1 decreases the
chemosensitivity of gastric cancer cells to oxaliplatin by
regulating FASN expression. Oncol Rep. 37:2583–2592. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith S, Witkowski A and Joshi AK:
Structural and functional organization of the animal fatty acid
synthase. Prog Lipid Res. 42:289–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szolkiewicz M, Nieweglowski T, Korczynska
J, Sucajtys E, Stelmanska E, Goyke E, Swierczynski J and Rutkowski
B: Upregulation of fatty acid synthase gene expression in
experimental chronic renal failure. Metabolism. 51:1605–1610. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Liu JY, Wu X and Zhang JT:
Biochemistry, molecular biology, and pharmacology of fatty acid
synthase, an emerging therapeutic target and diagnosis/prognosis
marker. Int J Biochem Mol Biol. 1:69–89. 2010.PubMed/NCBI
|
|
11
|
Heuer TS, Ventura R, Mordec K, Lai J,
Fridlib M, Buckley D and Kemble G: FASN Inhibition and Taxane
Treatment Combine to Enhance Anti-tumor Efficacy in Diverse
Xenograft Tumor Models through Disruption of Tubulin Palmitoylation
and Microtubule Organization and FASN Inhibition-Mediated Effects
on Oncogenic Signaling and Gene Expression. EBioMedicine. 16:51–62.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papaevangelou E, Almeida GS, Box C,
deSouza NM and Chung YL: The effect of FASN inhibition on the
growth and metabolism of a cisplatin-resistant ovarian carcinoma
model. Int J Cancer. 143:992–1002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ventura R, Mordec K, Waszczuk J, Wang Z,
Lai J, Fridlib M, Buckley D, Kemble G and Heuer TS: Inhibition of
de novo Palmitate Synthesis by Fatty Acid Synthase Induces
Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting
Signaling Pathways, and Reprogramming Gene Expression.
EBioMedicine. 2:808–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Albiges L, Hakimi AA, Xie W, McKay RR,
Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, et
al: Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical
and Biological Correlations. J Clin Oncol. 34:3655–3663. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Camassei FD, Jenkner A, Ravà L, Bosman C,
Francalanci P, Donfrancesco A, Alò PL and Boldrini R: Expression of
the lipogenic enzyme fatty acid synthase (FAS) as a predictor of
poor outcome in nephroblastoma: An interinstitutional study. Med
Pediatr Oncol. 40:302–308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagaprashantha LD, Talamantes T, Singhal
J, Guo J, Vatsyayan R, Rauniyar N, Awasthi S, Singhal SS and Prokai
L: Proteomic analysis of signaling network regulation in renal cell
carcinomas with differential hypoxia-inducible factor-2α
expression. PLoS One. 8:e716542013. View Article : Google Scholar
|
|
18
|
Wang Q, Geng F, Zhou H, Chen Y, Du J,
Zhang X, Song D and Zhao H: MDIG promotes cisplatin resistance of
lung adenocar-cinoma by regulating ABC transporter expression via
activation of the WNT/β-catenin signaling pathway. Oncol Lett.
18:4294–4307. 2019.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Friedman AD: Wilms tumor. Pediatr Rev.
34:328–330; discussion 330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Werbrouck E, Van Gansbeke D, Vanreusel A
and De Troch M: Temperature Affects the Use of Storage Fatty Acids
as Energy Source in a Benthic Copepod (Platychelipus littoralis,
Harpacticoida). PLoS One. 11:e01517792016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cha YJ, Kim HM and Koo JS: Expression of
Lipid Metabolism-Related Proteins Differs between Invasive Lobular
Carcinoma and Invasive Ductal Carcinoma. Int J Mol Sci. 18:182017.
View Article : Google Scholar
|
|
23
|
Kim S, Lee Y and Koo JS: Differential
expression of lipid metabolism-related proteins in different breast
cancer subtypes. PLoS One. 10:e01194732015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aminzadeh S, Vidali S, Sperl W, Kofler B
and Feichtinger RG: Energy metabolism in neuroblastoma and Wilms
tumor. Transl Pediatr. 4:20–32. 2015.
|
|
25
|
Liu X, Wen F, Yang J, Chen L and Wei YQ: A
review of current applications of mass spectrometry for
neuroproteomics in epilepsy. Mass Spectrom Rev. 29:197–246.
2010.
|
|
26
|
Thomas S and Bonchev D: A survey of
current software for network analysis in molecular biology. Hum
Genomics. 4:353–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Glozak MA, Sengupta N, Zhang X and Seto E:
Acetylation and deacetylation of non-histone proteins. Gene.
363:15–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Sun K, Jiao S, Cai N, Zhao X, Zou
H, Xie Y, Wang Z, Zhong M and Wei L: High levels of SIRT1
expression enhance tumorigenesis and associate with a poor
prognosis of colorectal carcinoma patients. Sci Rep. 4:74812014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hao C, Zhu PX, Yang X, Han ZP, Jiang JH,
Zong C, Zhang XG, Liu WT, Zhao QD, Fan TT, et al: Overexpression of
SIRT1 promotes metastasis through epithelial-mesenchymal transition
in hepatocellular carcinoma. BMC Cancer. 14:9782014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang RH, Sengupta K, Li C, Kim HS, Cao L,
Xiao C, Kim S, Xu X, Zheng Y, Chilton B, et al: Impaired DNA damage
response, genome instability, and tumorigenesis in SIRT1 mutant
mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alberts AW, Strauss AW, Hennessy S and
Vagelos PR: Regulation of synthesis of hepatic fatty acid
synthetase: Binding of fatty acid synthetase antibodies to
polysomes. Proc Natl Acad Sci USA. 72:3956–3960. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stoops JK, Arslanian MJ, Oh YH, Aune KC,
Vanaman TC and Wakil SJ: Presence of two polypeptide chains
comprising fatty acid synthetase. Proc Natl Acad Sci USA.
72:1940–1944. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang Y, Yin X, Wu L, Qin Q and Xu J:
MAPK/P53-mediated FASN expression in bone tumors. Oncol Lett.
13:4035–4038. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O’Malley J, Kumar R, Kuzmin AN, Pliss A,
Yadav N, Balachandar S, Wang J, Attwood K, Prasad PN and Chandra D:
Lipid quantification by Raman microspectroscopy as a potential
biomarker in prostate cancer. Cancer Lett. 397:52–60. 2017.
View Article : Google Scholar
|
|
36
|
Patel AV, Johansson G, Colbert MC,
Dasgupta B and Ratner N: Fatty acid synthase is a metabolic
oncogene targetable in malignant peripheral nerve sheath tumors.
Neuro-oncol. 17:1599–1608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Diaz KP, Gondak R, Martins LL, de Almeida
OP, León JE, Mariano FV, Altemani A and Vargas PA: Fatty acid
synthase and Ki-67 immunoexpression can be useful for the
identification of malignant component in carcinoma ex-pleomorphic
adenoma. J Oral Pathol Med. 48:232–238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sangeetha M, Deepa PR, Rishi P, Khetan V
and Krishnakumar S: Global gene deregulations in FASN silenced
retinoblastoma cancer cells: Molecular and clinico-pathological
correlations. J Cell Biochem. 116:2676–2694. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ooi AT and Gomperts BN: Molecular
Pathways: Targeting Cellular Energy Metabolism in Cancer via
Inhibition of SLC2A1 and LDHA. Clin Cancer Res. 21:2440–2444. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Alwarawrah Y, Hughes P, Loiselle D,
Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG,
Thompson JW, et al: Fasnall, a Selective FASN Inhibitor, Shows
Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast
Cancer. Cell Chem Biol. 23:678–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wong A, Chen S, Yang LK, Kanagasundaram Y
and Crasta K: Lipid accumulation facilitates mitotic
slippage-induced adaptation to anti-mitotic drug treatment. Cell
Death Discov. 4:1092018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giro-Perafita A, Palomeras S, Lum DH,
Blancafort A, Viñas G, Oliveras G, Pérez-Bueno F, Sarrats A, Welm
AL and Puig T: Preclinical Evaluation of Fatty Acid Synthase and
EGFR Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res.
22:4687–4697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu T, Schubert C, Cummings MD, Bignan G,
Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, et
al: Design and synthesis of a series of bioavailable fatty acid
synthase (FASN) KR domain inhibitors for cancer therapy. Bioorg Med
Chem Lett. 28:2159–2164. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Singh R, Yadav V, Kumar S and Saini N:
MicroRNA-195 inhibits proliferation, invasion and metastasis in
breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Sci Rep. 5:174542015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shen M, Tsai Y, Zhu R, Keng PC, Chen Y,
Chen Y and Lee SO: FASN-TGF-β1-PD-L1 axis contributes to the
development of resistance to NK cell cytotoxicity of
cisplatin-resistant lung cancer cells. Biochim Biophys Acta Mol
Cell Biol Lipids. 1863:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tao T, Su Q, Xu S, Deng J, Zhou S, Zhuang
Y, Huang Y, He C, He S, Peng M, et al: Down-regulation of PKM2
decreases FASN expression in bladder cancer cells through
AKT/mTOR/SREBP-1c axis. J Cell Physiol. 234:3088–3104. 2019.
View Article : Google Scholar
|
